Compare ALM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALM | SYRE |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | 342 | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.5B |
| IPO Year | N/A | 2015 |
| Metric | ALM | SYRE |
|---|---|---|
| Price | $19.05 | $70.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $22.33 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 4.1M | 809.9K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $817.94 | N/A |
| Revenue Next Year | $158.05 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $13.93 |
| 52 Week High | $24.41 | $78.80 |
| Indicator | ALM | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 50.41 |
| Support Level | $19.08 | $65.93 |
| Resistance Level | $21.91 | $76.16 |
| Average True Range (ATR) | 1.42 | 3.88 |
| MACD | 0.06 | -0.88 |
| Stochastic Oscillator | 49.18 | 44.26 |
Almonty Industries Inc is engaged in the development of the Sangdong Mine in South Korea, and the Company is currently mining, processing, and shipping tungsten concentrate from the Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal (Panasqueira Mine). Additionally, the Company is evaluating its molybdenum project with inferred mineral resources on a separate property adjacent to the tungsten orebody at the Sangdong Mine, its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora (Valtreixal Mine), and the newly-acquired Gentung Browns Lake tungsten project located in Montana, USA (Gentung-Browns Lake Project). The company has two geographical locations: the Iberian Peninsula (Spain and Portugal) and the Republic of Korea.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.